Michael Hai Luu Nguyen, Ph.D.’s Post

#News: Regeneron Pharmaceuticals is expanding its #celltherapy research, announcing a deal Tuesday to acquire the #drugpipeline of 2seventy bio and bring on many of the smaller #biotechnology company’s employees. The experimental #celltherapies #Regeneron acquires will be housed in a newly created research and development unit called Regeneron Cell Medicines, to be led by 2seventy’s top scientist Phil Gregory. Approximately 150 staff from 2seventy will join Gregory in transitioning to Regeneron. “Our expertise in antibody technologies and emerging genetics capabilities, combined with 2seventy’s cell therapy platforms, presents a significant opportunity to address cancer and other serious diseases in new and impactful ways,” said george yancopoulos, Regeneron’s chief scientific officer, in a statement. Regeneron will pay $5 million upfront for full rights to 2seventy’s experimental drug programs, a tiny sum for much of a company that spun out of bluebird bio two years ago with considerable buzz and more than $400 million in cash. Shares in 2seventy have lost much of their value since then, however, amid slow research progress and an ebbing market for biotech stocks. Last September, the company cut 40% of its workforce in a major restructuring meant to extend its operating runway. Read more from Yahoo Finance 👇🏼 https://lnkd.in/dYC9GF5g

What are Wave 3 biologics and why are they attracting little to no biosimilar competition? Wave 3 biologics are the latest wave of complex biologics characterized by rising levels of manufacturing, clinical testing and logistical complexity. This cohort comprises antibody-drug conjugates (ADC), cell and gene therapies (or Advanced Therapy Medicinal Products; ATMPs), oligonucleotides and PD-1 inhibitors. Wave 3 includes products facing LoE (loss of exclusivity) events by 2032. Although not all of these products target rare diseases, a rising share of them do. There are currently no candidates for any of these complex orphan drugs, but there are 16 candidates for non-orphan, Wave 3 biologics. The chart shows the pipeline for these biologics, which includes an early asset (Phase I) referencing trastuzumab emtansine, eight biosimilar candidates for pembolizumab and seven for nivolumab. Yet, not all these candidates are expected to progress to clinical trials or enter the European market following the expiry of patents and other exclusivity rights because of challenges to development and feasibility. IQVIA Institute’s Assessing the Biosimilars Void report further discusses the factors that affect the development and launch of new biosimilars for these complex biologics. Download the report here: https://bit.ly/47nFe3d. #ForecastLink #ArkPatent #IQVIAMIDAS #GlobalHealth #Datascience #Biosimilars

The pharmaceutical industry is amid a transformative era, witnessing profound changes in its commercial landscape. Key drivers for this transformation include the ascendancy of oncology as the largest therapeutic area in both sales and research and development (R&D) investments, the growing importance of biologics, gene therapies, and digital therapeutics, the evolving regulatory landscape emphasizing privacy, compliance, and healthcare cost reduction and, not less important, the digital transformation and the covid 19 pandemic. Our colleague Lourenço de Magalhães Pereira provides a view on what factors are driving the change in commercial strategies, and the potential impact these changes might have on the industry’s future. To access and download the article please go to is https://lnkd.in/e2dzrjam #lifesciences #pricing #contracting #commercialexcellence #lisbon #wth #princetonnj #geneva Ralph Lynn Arnab Sikder

The pharmaceutical industry is amid a transformative era, witnessing profound changes in its commercial landscape. Key drivers for this transformation include the ascendancy of oncology as one of the largest therapeutic area in both sales and research and development (R&D)investments, the growing importance of biologics, gene therapies, and digitaltherapeutics, the evolving regulatory landscape emphasizing privacy & compliance, healthcare cost reduction and, not less important, the continued digital transformation years after the covid 19 pandemic. Our colleague Lourenço de Magalhães Pereira provides a view on what factors are driving the change in commercial strategies, and the potential impact these changes might have on the industry’s future. To access and download the article please go to https://lnkd.in/eGci5c7x For further questions and insights please contact our Marbls team directly. #lifesciences #pricing #contracting #commercialexcellence #lisbon #wth #princetonnj #geneva Ralph Lynn Arnab Sikder

Another name to add to the AI in drug discovery watchlist: Xaira Therapeutics. The headlines rightly focus on the big (ok, really big - $1 billion) money and names behind this new "powerhouse". As yet, I can't find any solid details on its therapeutic areas or targets of interest, only that it plans to advance unspecified “multiple” drug programs. However, the company is advertising for a Head of Immunology and Inflammatory Diseases and a Head of Oncology. The source of its training data is also unclear at this stage. These are exciting times in the AI in drug discovery field with publication of preclinical and clinical models of INS018_055, a small-molecule TNIK inhibitor developed by by Insilico Medicine (https://lnkd.in/exdPgPND). The candidate has moved into Phase II trials. Exscientia is also making progress in the clinic with a CDK7 inhibitor currently in a Phase 1/2 clinical trial. The company anticipates initiating a Phase 1 patient study this year for its LSD1 inhibitor and continuing to progress its MALT1 inhibitor through IND-enabling studies this year. It certainly feels like the future of drug discovery is here. #drugdiscovery #AI #pharma https://lnkd.in/eci7ZcGk

Global Immuno-Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Design (Observational Trials, Interventional Trials) By Phase (Phase I, Phase IV, Phase II, Phase III) By Indication (Solid Tumors, Hematological Cancer), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031 Get This Report at Discounted Price: https://lnkd.in/d5Tu8AGZ Top Market Players: Agilex Biolabs Pty Ltd Alector Apollomics AstraZeneca BioNTech SE Biothera Pharmaceuticals, Inc. BioXcel Therapeutics, Inc. Bristol-Myers Squibb Pharma Company Covance Deep 6 AI Enterome Excelya Exscientia ICON plc Imvax, Inc. IO Biotech IQVIA iTeos Therapeutics LabConnect Labcorp Medelis, Inc. Median Technologies Medpace Merck KGaA, Darmstadt, Germany Merus N.V. Novartis OmniSeq OSE Immunotherapeutics Osivax Pfizer Pharmacyclics, an AbbVie Company Precision BioSciences, Inc. Premas Biotech RareCyte, Inc. Rubius Therapeutics Sonata Therapeutics Syneos Health The Conference Forum Virogin Biotech Xsphera Biosciences Inc

AstraZeneca is expanding in the U.S. and the new facility, slated for Rockville, Maryland, will increase their presence in the cell therapy sector. The Cambridge, UK based drug producer aims to manufacture T-cell therapies for clinical trials globally and is already anticipating further expansion into other segments. After converting the West Chester, OH location to Resilience in 2022, it will be interesting to see if this eventually leads to expansion in states such as NC, IN, KY, or TX. I suspect either a new location in Holly Springs or expansion of the existing space in Durham would be likely to occur first. But 🤷🏾♂️. It’s a bit too soon to know for sure. Regarding the new Maryland site, this will be the latest investment in cell therapy for AstraZeneca. Notable support for this through its collaborations with Quell Therapeutics, AbelZeta and Cellectis and acquisition of Neogene Therapeutics. #expansion #biopharma #manufacturing #astrazeneca #biotech #science #celltherapy #therapeutics #biologics #research #researchanddevelopment #tcell #biotechnologyindustry

Boosting a novel delivery platform for RNA therapeutics: ETH Zürich spin-off Procavea Biotech receives the CHF 150,000 Venture Kick funding. Congrats and best of success in the new year and beyond - cheers for the team of innovators Michael Wetter, Tom Edwardson, Richard Quaderer, and Donald Hilvert! https://lnkd.in/euA-r2_W About: Procavea Biotech is on a mission to revolutionize the delivery of RNA therapeutics and small molecule drugs. The company brings a first-in-class protein-based delivery platform for oligonucleotides and small molecules to the market. The technology was developed by at ETHZ and is protected in two patents. The current focus is on the Antisense and RNAi Therapeutics market, where there is great need for innovative delivery solutions. Procavea's target customers are pharmaceutical companies who will gain a competitive advantage by using our unique technology. Through strategic partnerships the company will license out bespoke delivery systems at various stages of development to meet its customers' needs. Long term Procavea Biotech aims to develop its own therapeutic pipeline. #VentureKick #SwissStartups

💉𝗖𝗔𝗥 𝗧 𝗖𝗲𝗹𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗯𝘆 𝗦𝗮𝗹𝗲𝘀 𝗶𝗻 𝟮𝟬𝟮𝟯 💸 🔵 The global CAR T cell therapy market size is likely to be worth USD 4.6 billion in 2024, and is projected to reach USD 25 billion by 2035, growing at a CAGR of 20% during the period 2024-2035. 🔵 CAR-T cell therapies have firmly established themselves in the pharmaceutical industry, with ongoing innovations propelling the field forward! ⭐ Here's an overview of the current landscape: 🔷 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 🔹 Around 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, with nearly 60% of these trials actively recruiting patients. 🔹 Nearly 300 therapies are targeting oncological disorders in the early stages of development. 🔷 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗣𝗿𝗲𝘀𝗲𝗻𝗰𝗲: 🔹 More than 190 CAR-T cell therapy companies are actively working on potential treatments for oncological, non-oncological, and other disorders. 🔷 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀: 🔹 There are over 260 partnerships and collaborations between industry and academic stakeholders aimed at expediting the development of pipeline candidates. 🔷 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀: 🔹 Capital investments totaling more than USD 32 billion have been made by both private and public sector investors in recent years. 🔷 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: 🔹 Over 10,000 patents have been filed or granted related to CAR-T cell therapies. 🔷 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 1️⃣ #Yescarta (anti-CD19) ⏩ Kite Pharma 2️⃣ #Abecma (anti-BCMA) ⏩ Bristol Myers Squibb 3️⃣ #Kymriah (anti-CD19) ⏩ Novartis 4️⃣ #Carvykti (anti-BCMA) ⏩ Janssen Inc. 5️⃣ #Tecartus (anti-CD19) ⏩ Kite Pharma 6️⃣ #Breyanzi (anti-CD19) ⏩ Bristol Myers Squibb 📚 Source: Companies' Annual Reports, Roots Analysis Report #cartcelltherapy #celltherapy #genetherapy #bigpharma #biologicals #pharmaceuticalindustry #biotechnology #marketresearch #pharma #biopharma #annualsales #topseller

The global CAR T cell therapy market size is likely to be worth USD 4.6 billion in 2024, and is projected to reach USD 25 billion by 2035, growing at a CAGR of 20% during the period 2024-2035. #globalmarket #growthstrategy #2024healthtrends